A Phase 1 Study of TORL-1-23 in People With Advanced Solid Tumors

Full Title

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 In Participants with Advanced Cancer (TORL123-001)

Purpose

Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.

TORL-1-23 is made of two parts. One part binds to a protein on cancer cells called Claudin 6, which plays a role in cancer cell growth. The other part is an anti-cancer drug that enters and kills the cells, with less risk of harming normal cells. TORL-1-23 is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Emily Slotkin’s office at 212-639-8856.